Entering text into the input field will update the search result below

Nektar launches two early-stage NKTR-358 studies

Oct. 08, 2019 6:57 AM ETNektar Therapeutics (NKTR) StockNKTRBy: Douglas W. House, SA News Editor4 Comments
  • Nektar Therapeutics (NASDAQ:NKTR) initiates two Phase 1b clinical trials evaluating NKTR-358 in psoriasis and atopic dermatitis, respectively.
  • The randomized plaque psoriasis study will enroll ~40 adults. Exploratory objectives includes assessments of disease activity and biomarkers.
  • The randomized atopic dermatitis study will also enroll ~40 adults and will have the same exploratory objectives.
  • Another Phase 1b trial evaluating NKTR-358 in systemic lupus erythematosus is in process.
  • The company refers to NKTR-358 as a resolution therapeutic that may bring the immune system back into balance by activating regulatory T cells via targeting the interleukin (IL-2) receptor complex in the body.

Recommended For You

About NKTR Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
NKTR--
Nektar Therapeutics